Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials

被引:49
|
作者
Alosh, Mohamed [1 ]
Huque, Mohammad F. [2 ]
Bretz, Frank [3 ,4 ]
D'Agostino, Ralph B., Sr. [5 ]
机构
[1] US FDA, Div Biometr 3, Off Biostat, OTS,CDER, Silver Spring, MD 20993 USA
[2] US FDA, Off Biostat, OTS, CDER, Silver Spring, MD 20993 USA
[3] Novartis, Stat Methodol & Consulting, Basel, Switzerland
[4] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria
[5] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA
关键词
negative subgroup treatment effect; treatment-by-subgroup interaction; supportive subgroup findings; targeted subgroup; MULTIPLE END-POINTS; SEVERE SEPSIS; DESIGN; ENRICHMENT; ALPHA; CONSISTENCY; FRAMEWORK; EFFICACY; CANCER;
D O I
10.1002/sim.7167
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Clinical trials target patients who are expected to benefit from a new treatment under investigation. However, the magnitude of the treatment benefit, if it exists, often depends on the patient baseline characteristics. It is therefore important to investigate the consistency of the treatment effect across subgroups to ensure a proper interpretation of positive study findings in the overall population. Such assessments can provide guidance on how the treatment should be used. However, great care has to be taken when interpreting consistency results. An observed heterogeneity in treatment effect across subgroups can arise because of chance alone, whereas true heterogeneity may be difficult to detect by standard statistical tests because of their low power. This tutorial considers issues related to subgroup analyses and their impact on the interpretation of findings of completed trials that met their main objectives. In addition, we provide guidance on the design and analysis of clinical trials that account for the expected heterogeneity of treatment effects across subgroups by establishing treatment benefit in a pre-defined targeted subgroup and/or the overall population. Copyright (C) 2016 John Wiley & Sons, Ltd.
引用
收藏
页码:1334 / 1360
页数:27
相关论文
共 50 条
  • [1] Statistical Considerations on Subgroup Analysis in Clinical Trials
    Alosh, Mohamed
    Fritsch, Kathleen
    Huque, Mohammad
    Mahjoob, Kooros
    Pennello, Gene
    Rothmann, Mark
    Russek-Cohen, Estelle
    Smith, Fraser
    Wilson, Stephen
    Yue, Lilly
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2015, 7 (04): : 286 - 304
  • [2] General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trials
    Dmitrienko, Alex
    Muysers, Christoph
    Fritsch, Arno
    Lipkovich, Ilya
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2016, 26 (01) : 71 - 98
  • [3] ADAPTIVE DESIGNS FOR CONFIRMATORY CLINICAL TRIALS WITH SUBGROUP SELECTION
    Stallard, Nigel
    Hamborg, Thomas
    Parsons, Nicholas
    Friede, Tim
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (01) : 168 - 187
  • [4] AN OVERVIEW OF STATISTICAL PLANNING TO ADDRESS SUBGROUPS IN CONFIRMATORY CLINICAL TRIALS
    Koch, Gary G.
    Schwartz, Todd A.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (01) : 72 - 93
  • [5] Flexible Bayesian subgroup analysis in early and confirmatory trials
    Bunn, Veronica
    Liu, Rachael
    Lin, Junjing
    Lin, Jianchang
    CONTEMPORARY CLINICAL TRIALS, 2020, 98
  • [6] Subgroup selection in adaptive signature designs of confirmatory clinical trials
    Zhang, Zhiwei
    Li, Meijuan
    Lin, Min
    Soon, Guoxing
    Greene, Tom
    Shen, Changyu
    JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS, 2017, 66 (02) : 345 - 361
  • [7] A Statistical Framework for Decision Making in Confirmatory Multipopulation Tailoring Clinical Trials
    Millen, Brian A.
    Dmitrienko, Alex
    Ruberg, Stephen
    Shen, Lei
    DRUG INFORMATION JOURNAL, 2012, 46 (06): : 647 - 656
  • [8] Subgroup analyses in confirmatory clinical trials: time to be specific about their purposes
    Tanniou, Julien
    van der Tweel, Ingeborg
    Teerenstra, Steven
    Roes, Kit C. B.
    BMC MEDICAL RESEARCH METHODOLOGY, 2016, 16
  • [9] Statistical Considerations for the Next Generation of Clinical Trials
    Wu, Wenting
    Shi, Qian
    Sargent, Daniel J.
    SEMINARS IN ONCOLOGY, 2011, 38 (04) : 598 - 604
  • [10] Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials
    Collignon, Olivier
    Gartner, Christian
    Haidich, Anna-Bettina
    Hemmings, Robert James
    Hofner, Benjamin
    Petavy, Frank
    Posch, Martin
    Rantell, Khadija
    Roes, Kit
    Schiel, Anja
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (05) : 1059 - 1067